Mainz Biomed N.V. announced that ColoAlert® has received official registration with the Medicines and Healthcare products Regulatory Agency (MHRA) and is now authorized for marketing in the United Kingdom. This follows a technology partnership with EDX Medical Group plc earlier this year.
Colorectal cancer is the fourth most common cancer in the UK, with approximately 44,000 new cases diagnosed annually. ColoAlert provides a non-invasive approach to CRC screening by detecting DNA biomarkers in stool samples, aiming to complement the existing Bowel Cancer Screening Program.
This regulatory milestone enables Mainz Biomed’s UK laboratory partner to provide a reliable and user-friendly test to a large population. The approval supports the shared goal of increasing participation in preventive screening and ultimately saving more lives in the UK.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.